

1 **Comparison of the Effect of Intraoperative 1 mg/kg/h and 2 mg/kg/h IV Lidocaine**
2 **Infusion on Postoperative Pain and Nausea-Vomiting in Laparoscopic Gastric**
3 **Bypass Surgery**

4 **Objective:** To relieve postoperative pain and nausea and vomiting, various drugs and
5 methods, including intraoperative IV lidocaine infusion in different surgeries. However, the
6 exact dose has not yet been determined. The purpose of this study was to evaluate and
7 compare the effect of intraoperative 1 mg/kg/h and 2 mg/kg/h IV lidocaine infusion on
8 postoperative pain and nausea-vomiting in laparoscopic gastric bypass surgery.

9 **Methods:** This clinical trial study was performed on patients undergoing laparoscopic
10 gastric bypass surgery in Rasoul-e-Akram Hospital, Iran. Patients were randomly assigned
11 into two groups (1 mg/kg/h lidocaine) and (2 mg/kg/h lidocaine). Postoperative pain and
12 nausea and vomiting were evaluated at times 0, 30 min, 1 h, 6 h, 12 h and 24 h after surgery.
13 Data was analyzed using statistical tests and SPSS 22.

14 **Results:** There was no significant difference in the effect of intraoperative 1 mg/kg/h and 2
15 mg/kg/h IV lidocaine infusion on static and dynamic pain and nausea-vomiting, agitation,
16 systolic BP, diastolic BP, pulse rate and postoperative administration of pethidine in
17 laparoscopic gastric bypass ($P>0.05$).

18 **Conclusion:** Based on results of this study, administration of low dose lidocaine (1 mg/kg/h)
19 can be considered as an appropriate dose of IV lidocaine infusion in order to control
20 postoperative pain and nausea and vomiting in laparoscopic gastric bypass surgery.

21 **Keywords:** lidocaine, pain, nausea-vomiting, gastric bypass

22 **1. Introduction**

23 In post-operative time, it is important to control and reduce postoperative pain and nausea-
24 vomiting (1). Different drugs and methods are used to relieve postoperative pain and nausea
25 and vomiting in different surgeries (2). One of these methods, which has been studied on
26 numerous occasions, is intraoperative intravenous (IV) lidocaine infusion undergone in a
27 wide range of surgical procedures such as laparotomy, laparoscopy, gynecological surgery,
28 orthopedics, etc., and has a positive effect in most cases in reducing postoperative pain and
29 nausea-vomiting (3). Considering the pharmacological effects of IV lidocaine, which has
30 both anti-inflammatory and analgesic effects (protein receptor inhibitor G and NMDA),
31 lidocaine has been used to relieve postoperative pain (4). According to numerous studies on
32 various surgical procedures, intraoperative IV lidocaine infusion has been shown to reduce
33 postoperative pain and nausea and vomiting (5-14). Although the exact dosage is still
34 unknown, the conducted studies have used 1-2 mg/kg/h dosages. In a double-blind clinical
35 trial on 41 patients undergoing microdiscectomy in two groups receiving 1.5 mg/kg/h lidocaine
36 infusion and normal saline infusion as placebo, Kim et al (2014) concluded that fentanyl

37 administration and postoperative pain intensity were significantly lower in the lidocaine
38 group except 48 hours after surgery. Total fentanyl administration, hospital stay and
39 satisfaction were significantly lower in lidocaine group than placebo group. Finally,
40 intraoperative systemic infusion of lidocaine reduces pain level during **microdiscectomy**
41 surgery (6). According to the studies, this study tends to evaluate and compare the effect of
42 intraoperative 1 mg/kg/h and 2 mg/kg/h IV lidocaine infusion on postoperative pain and
43 nausea-vomiting in laparoscopic gastric bypass to determine a more suitable and effective
44 dosage.

45 **2. Materials and Methods**

46 This study was a randomized clinical trial. The studied population included elective patients
47 who were candidate for laparoscopic gastric bypass referred to Rasoul-e-Akram Hospital
48 since June 2014 to March 2015. Sampling method was convenient sampling. Sample size was
49 determined using Cohen table with 80% statistical power, 0.05 alpha and 0.9 accuracy (21
50 subjects in each group). This study was a randomized clinical trial. Block randomization was
51 done in quadrilateral blocks. This study was performed on 42 elective patients who were
52 candidate for laparoscopic gastric bypass referred to Rasoul-e-Akram Hospital since June
53 2014 to March 2015. After obtaining consent and qualifying patients for inclusion and
54 exclusion, 41 patients were assigned into 2 groups of 21 patients (A and B) in 4 blocks. After
55 entering the operating room, standardized monitoring (ECG-POM-NIBP-Etco2) and insertion
56 of two 20G IV catheters and 3 cc/kg **normal saline 0.9% Serum** infusion were performed for
57 all patients. Then, 3 mcg/kg fentanyl based on TBW and 20 mcg/kg midazolam based on
58 TBW were administered as premedication for all patients. For induction, all patients received
59 5 mg/kg thiopental sodium based on TBW followed by 0.2 mg/kg atracurium based on IBW
60 and 1.5 mcg/kg bolus lidocaine based on IBW for general anesthesia. After intubation of the
61 patients, all of them received 1.2 mac isoflurane followed by 0.03 mg/kg atracurium every 30
62 minutes and 50 mcg fentanyl every 40 minutes as maintenance. From the beginning of
63 surgery, group A received 1 mg/kg/h IV lidocaine infusion and group B received 2 mg/kg/h
64 IV lidocaine infusion by the pump until the end of surgery for a maximum of 4 hours. After
65 the end of surgery and discontinuation of all drugs, patients were placed in reserve by 0.04
66 mg/kg **neostigmine** and 0.02 mg/kg atropine and extubation was done; . The time to enter
67 recovery was set at t=0; for 24 h, patients were monitored for pain based on numerical rating

68 score (0-10), static and dynamic nausea-vomiting, blood pressure (BP), heart rate and
 69 agitation in predicted times in the recovery or surgery wards.
 70 Finally, data was analyzed by SPSS software version 22. In the analytical step, Kolmogorov-
 71 Sminov test was used for determining normality of quantitative values. Then, independent T-
 72 test or Mann-Whitney U-test were used for comparing the quantitative variables of two
 73 groups A and B. Chi-square test (Z) was used to compare the qualitative variables. Repeated
 74 measure ANOVA or Friedman test was used to check and compare the changes.

75 3. Results

76 In this study, 42 patients who were referred to surgery ward of the Rasoul-e-Akram Hospital
 77 in 2016 and underwent laparoscopic elective gastric bypass were enrolled in the study. In
 78 group A, 21 patients (50%) received intraoperative 1 mg/kg/h IV lidocaine infusion; in group
 79 B, 21 patients (50%) received intraoperative 2 mg/kg/h IV lidocaine infusion.

80 The patients aged 18-49 years (36.15 ± 6.88); 18 patients (42.9%) were male and 24 patients
 81 (57.1%) were female. BMI was 38-46 Kg/m² (42.23 ± 2.22 Kg/m²). Ten patients (23.8%)
 82 were in Class ASA 1, 25 patients (59.5%) were in Class ASA 2 and 7 patients (16.7%) were
 83 in Class ASA 3.

84 According to the patients, 16 people (38.1%) had a history of hypertension. None of the
 85 patients had a history of heart disease. Four patients (9.5%) had a history of diabetes, 9
 86 patients (21.4%) had a history of fatty liver disease, and 8 (19%) had a history of other
 87 diseases.

88 In terms of the history of previous drugs, 5 patients (11.9%) took cigarette, 4 patients (9.5%)
 89 took loratadine, 3 (7.1%) took metoral, 4 (9.5%) took metformin, 2 (4.8%) took
 90 levothyroxine, 1 (2.4%) took loratadine and levothyroxine, 4 (9.5%) took loratadine and
 91 metformin, 1 (2.4%) took atenolol and levothyroxine, 2 (4.8%) took metformin and
 92 glibenclamide, 2 (4.8%) took metformin and metoral, and 1 (2.4%) took loratadine and
 93 metformin and hydroxin. Descriptive characteristics and comparison of age and gender of
 94 patients undergoing elective laparoscopic gastric bypass in two groups A and B are
 95 summarized in Table 1.

96 **Table 1: Descriptive characteristics and comparison of age and gender of patients undergoing elective laparoscopic**
 97 **gastric bypass in two groups A and B**

Characteristic	Group		P-Value
	A	B	
Age (year) Mean \pm SD	34.48 \pm 5.34	37.9 \pm 7.96	0.11
Gender			1

Male	9 (42.9%)	9 (42.9%)
Female	12 (57.1%)	12 (57.1%)

98 According to Table 1, there is no significant difference in age and gender of patients
 99 undergoing elective laparoscopic gastric bypass between two groups A and B ($P>0.05$).

100 **3.1. Determining and Comparing Pain in Two Groups A and B Based on Numerical Rating**
 101 **Score at Times 0, 30 min, 1 h, 6 h, 12 h and 24 h after Laparoscopic Gastric Bypass**

102 In order to compare the pain level in 2 groups A and B based on numerical rating score at
 103 times 0, 30 min, 1 h, 6 h, 12 h, and 24 h after laparoscopic gastric bypass, the Mann-Whitney
 104 U-test was used. Friedman test was used for comparison at times 0, 30 min, 1 h, 6 h, 12 h and
 105 24 h after laparoscopic gastric bypass in each of the two groups A and B (separately).
 106 Descriptive features and comparison of pain levels are summarized in Table 2.

107

108 **Table 2: descriptive features and comparison of pain level in two groups A and B based on numerical rating score at**
 109 **times 0, 30 min, 1 h, 6 h, 12 h and 24 h after laparoscopic gastric bypass**

Time	Group		Test statistic	p-value
	A (mean \pm SD)	B (mean \pm SD)		
0	1.67 \pm 1.01	1.71 \pm 0.78	0.014	0.989
30 min	2.67 \pm 0.73	2.67 \pm 0.65	0.139	0.889
1 h	3.29 \pm 0.84	3.19 \pm 0.98	0.346	0.729
6 h	5.71 \pm 0.9	5.57 \pm 1.2	0.898	0.369
12 h	4.86 \pm 0.96	4.71 \pm 0.95	0.404	0.687
24 h	3.95 \pm 1.39	3.81 \pm 1.03	0.199	0.842
-	$P<0.001$, $X^2=94.18$	$P<0.001$, $X^2=88.29$	-	-

110 Based on the results of Table 2, there was no significant difference between pain levels of
 111 patients in 2 groups A and B based on numerical rating score at times 0, 30 min, 1 h, 6 h, 12
 112 h, and 24 h after laparoscopic gastric bypass ($P>0.05$). There was a significant difference
 113 between pain levels of patients based on numerical rating score at times 0, 30 min, 1 h, 6 h,
 114 12 h, and 24 h after laparoscopic gastric bypass in group A ($P<0.001$, $X^2=94.18$). There was a
 115 significant difference between pain levels of patients based on numerical rating score at times
 116 0, 30 min, 1 h, 6 h, 12 h, and 24 h after laparoscopic gastric bypass in group B ($P<0.001$,
 117 $X^2=88.29$).

118 **3.2. Determining and Comparing Static Nausea-Vomiting in Two Groups A and B at Times 0,**
 119 **30 min, 1 h, 6 h, 12 h and 24 h after Laparoscopic Gastric Bypass**

120 In order to compare static nausea-vomiting levels in 2 groups A and B after laparoscopic
 121 gastric bypass, Z-test was used. Friedman test was used for comparison at times 0, 30 min, 1
 122 h, 6 h, 12 h and 24 h after laparoscopic gastric bypass in each of the two groups A and B
 123 (separately). Frequency values and nausea-vomiting comparison are summarized in Table 3.

124
125

Table 3: descriptive features and comparison of static nausea-vomiting levels in two groups A and B after laparoscopic gastric bypass

Time	Group		Test statistic	p-value
	A (N, %)	B (N, %)		
0	2 (9.5%)	5 (23.8%)	1.26	0.896
30 min	4 (19%)	3 (14.3%)	0.4	0.655
1 h	0 (0%)	1 (4.8%)	0.22	0.587
6 h	0 (0%)	0 (0%)	0	0.5
12 h	0 (0%)	0 (0%)	0	0.5
24 h	0 (0%)	0 (0%)	0	0.5
	P=0.01, X ² =15	P=0.008, X ² =15.73		

126 Based on the results of Table 3, there was no significant difference between static nausea-
 127 vomiting levels of patients in 2 groups A and B at times 0, 30 min, 1 h, 6 h, 12 h, and 24 h
 128 after laparoscopic gastric bypass (P>0.05). There was a significant difference between static
 129 nausea-vomiting levels of patients at times 0, 30 min, 1 h, 6 h, 12 h, and 24 h after
 130 laparoscopic gastric bypass in group A (P=0.01, X²=15). There was a significant difference
 131 between static nausea-vomiting levels of patients at times 0, 30 min, 1 h, 6 h, 12 h, and 24 h
 132 after laparoscopic gastric bypass in group B (P=0.008, X²=15.73).

133 **3.3. Determining and Comparing Dynamic Nausea-Vomiting in Two Groups A and B at Times**
 134 **0, 30 min, 1 h, 6 h, 12 h and 24 h after Laparoscopic Gastric Bypass**

135 In order to compare dynamic nausea-vomiting levels in 2 groups A and B after laparoscopic
 136 gastric bypass, Z-test was used. Friedman test was used for comparison at times 0, 30 min, 1
 137 h, 6 h, 12 h and 24 h after laparoscopic gastric bypass in each of the two groups A and B
 138 (separately). Frequency values and nausea-vomiting comparison are summarized in Table 4.

139 **Table 4: descriptive features and comparison of dynamic nausea-vomiting levels in two groups A and B after**
 140 **laparoscopic gastric bypass**

Time	Group		Test statistic	p-value
	A (N, %)	B (N, %)		
0	8 (38.1%)	6 (28.6%)	0.65	0.742
30 min	14 (66.7%)	11 (52.4%)	0.95	0.828
1 h	5 (23.8%)	5 (23.8%)	0	0.5
6 h	0 (0%)	0 (0%)	0	0.5
12 h	0 (0%)	0 (0%)	0	0.5
24 h	0 (0%)	0 (0%)	0	0.5
	P=0.001, X ² =45	P=0.001, X ² =33.77		

141 Based on the results of Table 4, there was no significant difference between dynamic nausea-
 142 vomiting levels of patients in 2 groups A and B at times 0, 30 min, 1 h, 6 h, 12 h, and 24 h
 143 after laparoscopic gastric bypass (P>0.05). There was a significant difference between
 144 dynamic nausea-vomiting levels of patients at times 0, 30 min, 1 h, 6 h, 12 h, and 24 h after
 145 laparoscopic gastric bypass in group A (P=0.001, X²=45). There was a significant difference

146 between dynamic nausea-vomiting levels of patients at times 0, 30 min, 1 h, 6 h, 12 h, and 24
 147 h after laparoscopic gastric bypass in group B ($P=0.001$, $X^2=33.77$).

148 **3.4. Determining and Comparing Agitation in Two Groups A and B at Times 0, 30 min and 1 h**
 149 **after Surgery**

150 In order to compare agitation levels in 2 groups A and B after laparoscopic gastric bypass, Z-
 151 test was used. Friedman test was used for comparison at times 0, 30 min and 1 h after surgery
 152 in each of the two groups A and B (separately). Frequency values and agitation comparison
 153 are summarized in Table 5.

154 **Table 5: descriptive features and comparison of agitation levels in two groups A and B after laparoscopic gastric**
 155 **bypass**

Time	Group		Test statistic	p-value
	A (N, %)	B (N, %)		
0	6 (28.6%)	5 (23.8%)	0.35	0.636
30 min	5 (23.8%)	6 (28.6%)	0.35	0.636
1 h	1 (4.8%)	1 (4.8%)	0	0.5
-	$P=0.072$, $X^2=5.25$	$P=0.097$, $X^2=4.66$	-	-

156 Based on the results of Table 5, there was no significant difference between agitation levels
 157 of patients in 2 groups A and B at times 0, 30 min and 1 h after laparoscopic gastric bypass
 158 ($P>0.05$). There was no significant difference between agitation levels of patients at times 0,
 159 30 min and 1 h after laparoscopic gastric bypass in group A ($P=0.072$, $X^2=5.25$). There was
 160 no significant difference between agitation levels of patients at times 0, 30 min and 1 h after
 161 laparoscopic gastric bypass in group B ($P=0.097$, $X^2=4.66$).

162 **3.5. Determining and Comparing Systolic BP in Two Groups A and B at Times 0, 30 min and 1**
 163 **h after Laparoscopic Gastric Bypass**

164 In order to compare systolic BP levels in 2 groups A and B at times 0, 30 min and 1 h after
 165 laparoscopic gastric bypass, independent t-test and Mann-Whitney U-test were used.
 166 Friedman test and repeated measure test were used for comparison of systolic BP levels at
 167 times 0, 30 min and 1 h after laparoscopic gastric bypass in each of the two groups A and B
 168 (separately). Descriptive features and comparison of systolic BP are summarized in Table 6.

169 **Table 6: descriptive features and comparison of systolic BP levels in two groups A and B at times 0, 30 min and 1 h**
 170 **after laparoscopic gastric bypass**

Time	Group		Test statistic	p-value
	A (mean \pm SD)	B (mean \pm SD)		
0	141.76 \pm 13.68	141.9 \pm 14.92	0.032	0.974
30 min	139.33 \pm 13.13	139.43 \pm 15.27	0.025	0.98
1 h	134.05 \pm 11.38	136.48 \pm 10.42	0.768	0.477
-	$P<0.001$, $X^2=27.71$	$P=0.012$, $X^2=5.59$	-	-

171 Based on the results of Table 6, there was no significant difference between systolic BP
 172 levels of patients in 2 groups A and B at times 0, 30 min and 1 h after laparoscopic gastric
 173 bypass ($P>0.05$). There was a significant difference between systolic BP levels of patients at
 174 times 0, 30 min and 1 h after laparoscopic gastric bypass in group A ($P<0.001$, $X^2=27.71$).
 175 There was a significant difference between systolic BP levels of patients at times 0, 30 min
 176 and 1 h after laparoscopic gastric bypass in group B ($P=0.012$, $X^2=5.59$).

177 **3.6. Determining and Comparing Diastolic BP in Two Groups A and B at Times 0, 30 min and 1**
 178 **h after Laparoscopic Gastric Bypass**

179 In order to compare diastolic BP levels in 2 groups A and B at times 0, 30 min and 1 h after
 180 laparoscopic gastric bypass, independent t-test was used. Repeated measure test was used for
 181 comparison of diastolic BP levels at times 0, 30 min and 1 h after laparoscopic gastric bypass
 182 in each of the two groups A and B (separately). Descriptive features and comparison of
 183 diastolic BP are summarized in Table 7.

184 **Table 7: descriptive features and comparison of diastolic BP levels in two groups A and B at times 0, 30 min and 1 h**
 185 **after laparoscopic gastric bypass**

Time	Group		Test statistic	p-value
	A (mean ± SD)	B (mean ± SD)		
0	91.24 ± 8.24	93.05 ± 9.71	0.651	0.519
30 min	89.57 ± 9.3	91.19 ± 11.27	0.508	0.615
1 h	86.24 ± 9.54	89.14 ± 7.35	1.18	0.245
-	$P<0.001$, $X^2=58.94$	$P=0.001$, $X^2=11.38$	-	-

186 Based on the results of Table 7, there was no significant difference between diastolic BP
 187 levels of patients in 2 groups A and B at times 0, 30 min and 1 h after laparoscopic gastric
 188 bypass ($P>0.05$). There was a significant difference between diastolic BP levels of patients at
 189 times 0, 30 min and 1 h after laparoscopic gastric bypass in group A ($P<0.001$, $X^2=58.94$).
 190 There was a significant difference between diastolic BP levels of patients at times 0, 30 min
 191 and 1 h after laparoscopic gastric bypass in group B ($P=0.001$, $X^2=11.38$).

192 **3.7. Determining and Comparing Heart Rate in Two Groups A and B at Times 0, 30 min and 1**
 193 **h after Laparoscopic Gastric Bypass**

194 In order to compare heart rate in 2 groups A and B at times 0, 30 min and 1 h after
 195 laparoscopic gastric bypass, independent t-test and Mann-Whitney test were used. Repeated
 196 measure test and Friedman test were used for comparison of heart rate at times 0, 30 min and
 197 1 h after laparoscopic gastric bypass in each of the two groups A and B (separately).
 198 Descriptive features and comparison of heart rate are summarized in Table 8.

Table 8: descriptive features and comparison of heart rate in two groups A and B at times 0, 30 min and 1 h after laparoscopic gastric bypass

Time	Group		Test statistic	p-value
	A (mean ± SD)	B (mean ± SD)		
0	93.05 ± 7.32	96.86 ± 6.64	1.76	0.085
30 min	90.29 ± 6.66	92.86 ± 8.31	1.26	0.207
1 h	86.43 ± 6.47	88 ± 7.44	0.9	0.364
	P<0.001, X ² =28.5	P=0.001, X ² =67.43		

201 Based on the results of Table 8, there was no significant difference between heart rate of
 202 patients in 2 groups A and B at times 0, 30 min and 1 h after laparoscopic gastric bypass
 203 (P>0.05). There was a significant difference between heart rate of patients at times 0, 30 min
 204 and 1 h after laparoscopic gastric bypass in group A (P<0.001, X²=28.5). There was a
 205 significant difference between heart rate of patients at times 0, 30 min and 1 h after
 206 laparoscopic gastric bypass in group B (P=0.001, X²=67.43).

207 3.8. Determining and Comparing the First, Second and Third Pethidine Administrations in Two 208 Groups A and B after Laparoscopic Gastric Bypass

209 In order to compare the first, second and third pethidine administrations in 2 groups A and B
 210 after laparoscopic gastric bypass, Z-test was used. Frequency values and comparison of the
 211 first, second and third pethidine administrations in groups A and B after laparoscopic gastric
 212 bypass are summarized in Table 9.

213 **Table 9: descriptive features and comparison of the first, second and third pethidine administrations in two groups A
 214 and B after laparoscopic gastric bypass**

Time	Group		Test statistic	p-value
	A (N, %)	B (N, %)		
1 st	6 (28.6%)	11 (52.3%)	1.61	0.053
2 nd	12 (57.1%)	8 (38%)	1.26	0.103
3 rd	3 (14.3%)	1 (4.8%)	1.06	0.144

215 Based on the results of Table 9, there was no significant difference between the first, second
 216 and third pethidine administrations in 2 groups A and B after laparoscopic gastric bypass
 217 (P>0.05).

218 4. Discussion

219 According to the most important results of this study, there was no significant difference
 220 between the effect of intraoperative 1 mg/kg/h and 2 mg/kg/h IV lidocaine infusion on
 221 postoperative pain, static and dynamic nausea-vomiting, agitation, systolic BP, diastolic BP,
 222 heart rate and pethidine administration after laparoscopic gastric bypass. In both groups,
 223 intraoperative 1 mg/kg/h and 2 mg/kg/h IV lidocaine infusion significantly increased pain 6

224 hours postoperatively and significantly decreased pain 24 hours postoperatively. Moreover,
225 postoperative static and dynamic nausea-vomiting, agitation, systolic BP, diastolic BP and
226 heart rate significantly decreased 0-24 hours after the surgery. Therefore, lidocaine seems to
227 reduce postoperative pain and complications. However, high-dose and low-dose lidocaine has
228 the same significant effect in reducing pain and complications after laparoscopic gastric
229 bypass.

230 Postoperative pain not only causes physical and mental torment, but also increases the risk of
231 side effects and delayed recovery. Therefore, it is important to eliminate emotional pain and
232 stress to maintain comfortable recovery, reduce the incidence of postoperative cardiovascular
233 complications and increase sooner discharge (15). It has been previously reported that
234 preoperative IV lidocaine infusion can increase postoperative analgesic effects and accelerate
235 early recovery; intraoperative continuous infusion can effectively prevent central hyperalgergy
236 through the pain pathway (16). Lidocaine has an insignificant opioid-sparing property in
237 patients undergoing various surgical procedures (17, 18). Several mechanisms have been
238 suggested to explain the insignificant opioid-sparing effect of preoperative lidocaine. First,
239 lidocaine has anti-inflammatory properties which can minimize the pain caused by surgical
240 inflammation (19, 20). Second, lidocaine also can directly block the pathways of pain
241 conducting sodium channels (21). Eventually, lidocaine can reduce the need for opioid drugs
242 or intraoperative volatile anesthetics, which may reduce the progression of postoperative pain
243 (22, 24).

244 Based on literature review, this study was the first study to compare the effects of two
245 different doses of lidocaine (1 mg/kg/h vs. 2 mg/kg/h IV infusion) on postoperative pain and
246 nausea-vomiting after laparoscopic gastric bypass. However, many studies have shown that
247 different doses of lidocaine infusion reduced postoperative pain level and side effects,
248 compared with placebo and other drugs. For example, Tikuišis et al (2014) studied 64
249 patients undergoing laparoscopic colon surgery and found that pain level significantly
250 decreased 24 h after the surgery in both rest and movement in 2 mg/kg/h lidocaine group
251 compared to placebo group. Moreover, there was no significant difference between
252 postoperative complications between the two groups (5). Through a meta-analysis, Ventham
253 et al. (2015) reviewed 40 clinical trials on comparing the effect of lidocaine infusion with
254 placebo or routine postoperative laparoscopic treatments and found that lidocaine
255 intervention reduced the pain score at rest in 2, 12 and 24 hours after surgery and reduced
256 nausea and vomiting (9). **Selcuk et al (2015)** studied 226 patients undergoing laparoscopic
257 gynecological surgery and revealed that 1% lidocaine infusion was more effective on

258 postoperative pain than placebo (12). Terkawi et al (2016) found no significant difference in
259 pain scores between the two groups by follow-up of 216 patients after 2 days of abdominal
260 surgery in two groups of 1 mg/kg/h IV Lidocaine infusion and epidural analgesia. In
261 lidocaine group, episodes of hypotension and postoperative nausea and vomiting were less
262 frequent than placebo group (14).

263 According to previous studies some of which has been noted in the previous paragraph, on a
264 certain dosage, pain and nausea-vomiting were not compared between two groups of 1
265 mg/kg/h and 2 mg/kg/h lidocaine; positive effect of lidocaine in reducing pain and nausea-
266 vomiting in most of these studies may be due to the fact that lidocaine has been compared
267 with opiate and placebo. Moreover, inconsistency of this study with some studies may be due
268 to differences in samples, design of studies, lidocaine doses and surgical site and procedures.

269 In the present study in which patients were carefully monitored for up to 24 hours after
270 surgery, although administration of high-dose lidocaine did not cause side effects after
271 surgery, administration of low doses, as high doses, reduced pain, nausea-vomiting and
272 agitation. Therefore, low doses of lidocaine (1 mg/kg/h), rather than high doses (2 mg/kg/h),
273 can be used as an appropriate dose of IV lidocaine infusion to control postoperative pain and
274 nausea-vomiting in laparoscopic gastric bypass.

275 **5. Conclusion**

276 Based on the results of this study, low doses of lidocaine (1 mg/kg/h), rather than high doses
277 (2 mg/kg/h), can be used as an appropriate dose of IV lidocaine infusion to control
278 postoperative pain and nausea-vomiting in laparoscopic gastric bypass.

279 Consent: After obtaining consent and qualifying patients for inclusion and exclusion, 41
280 patients were assigned into 2 groups of 21 patients (A and B) in 4 blocks.

281 Ethical: NA

282

283

284 **References**

285 1. Christopher L. Wu. Acute Postoperative Pain. In: Miller RD, ed. Miller's Anesthesia, 6th
286 ed.

287 Philadelphia; Churchill Livingstone, 2005; 2729- 2750.

288 2. McCracken G, Houston P, Lefebvre G.Guideline for the Management of Postoperative
289 Nausea and Vomiting. JULY JOGC JUILLET ;2008July No. 209.

- 290 3. McCarthy GC, Megalla SA, Habib AS. Impact of intravenous lidocaine infusion on
291 postoperative analgesia and recovery from surgery: a systematic review of randomized
292 controlled trials. *Drugs*. 2010 Jun 18;70(9):1149-63.
- 293 4. van der Wal SE , van den Heuvel SA , Radema SA , van Berkum BF , Vaneker M ,
294 Steegers MA, et al. The in vitro mechanisms and in vivo efficacy of intravenous lidocaine on
295 the neuroinflammatory response in acute and chronic pain. *Eur J Pain*. 2015 Dec 18.
- 296 5. Tikuišis R , Miliauskas P, Samalavičius NE, Žurauskas A, Samalavičius R, Zabulis V.
297 Intravenous lidocaine for post-operative pain relief after hand-assisted laparoscopic colon
298 surgery: a randomized, placebo-controlled clinical trial. *Tech Coloproctol*. 2014
299 Apr;18(4):373-80.
- 300 6. Kim KT, Cho DC, Sung JK, Kim YB, Kang H, Song KS, Choi GJ. Intraoperative systemic
301 infusion of lidocaine reduces postoperative pain after lumbar surgery: a double-blinded,
302 randomized, placebo-controlled clinical trial. *Spine J* 2014; 14:1559 –1566.
- 303 7. Patrick Tauzin-Fin, Olivier Bernard, Musa Sesay, Matthieu Biais, Philippe Richebe, Alice
304 Quinart, et al. Benefits of intravenous lidocaine on post-operative pain and acute
305 rehabilitation
306 after laparoscopic nephrectomy. *J Anaesthesiol Clin Pharmacol*. 2014 Jul-Sep; 30(3): 366–
307 372.
- 308 8. Kranke P, Jokinen J, Pace NL, Schnabel A, Hollmann MW, Hahnenkamp K, et al.
309 Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery.
310 *Cochrane Database Syst Rev*. 2015 Jul 16;7:CD009642
- 311 9. Ventham NT, Kennedy ED, Brady RR, Paterson HM, Speake D, Foo I, Fearon KC.
312 Efficacy of Intravenous Lidocaine for Postoperative Analgesia Following Laparoscopic
313 Surgery: A Meta-Analysis. *World J Surg*. 2015 Sep;39(9):2220-34.
- 314 10. Ahn E, Kang H, Choi GJ, Park YH, Yang SY, Kim BG, et al. Intravenous lidocaine for
315 effective pain relief after a laparoscopic colectomy: a prospective, randomized, double-blind,
316 placebocontrolled study. *Int Surg*. 2015 Mar;100(3):394-401.
- 317 11. Hesham F. Solimana, Ahmed R. Gharbiya . Efficacy of systemic lidocaine infusion
318 compared with systemic ketorolac infusion in improvement of recovery after laparoscopic
319 bariatric surgery. *Ain-Shams Journal of Anesthesiology*. 2015; 8: 334-40.
- 320 12. Selcuk S, Api M, Polat M, Arinkan A , Aksoy B, Akca T, et al. Effectiveness of local
321 anesthetic on postoperative pain in different levels of laparoscopic gynecological surgery.
322 *Arch Gynecol Obstet*. 2015 Dec 15. [Epub ahead of print]

- 323 13. Yang W, Hu WL. Effects of intravenously infused lidocaine on analgesia and
324 gastrointestinal function of patients receiving laparoscopic common bile duct exploration.
325 *Pak J Med Sci*. 2015 Sep-Oct;31(5):1073-7.
- 326 14. Terkawi AS, Tsang S, Kazemi A, Morton S, Luo R, Sanders DT, et al. A Clinical
327 Comparison of Intravenous and Epidural Local Anesthetic for Major Abdominal Surgery.
328 *Reg Anesth Pain Med*. 2016 Jan-Feb;41(1):28-36.
- 329 15. Hui V, Hyman N, Viscomi C, Osler T. Implementing a fasttrack protocol for patients
330 undergoing bowel resection: not so fast. *Am J Surg*. 2013;206(2):152-158.
- 331 16. Gil V, Parsons S, Gallego D, Huizinga J, Jimenez M. Effects of hydrogen sulphide on
332 motility patterns in the rat colon. *Br J Pharmacol*. 2013;169(1):34-50.
333
- 334 17. De Oliveira GS Jr, Duncan K, Fitzgerald P, Nader A, Gould RW, McCarthy RJ. Systemic
335 lidocaine to improve quality of recovery after laparoscopic bariatric surgery: a randomized
336 double-blinded placebocontrolled trial. *Obes Surg* 2014; 24:21 2–218.
- 337 18. Vigneault L, Turgeon AF, Côté D, Lauzier F, Zarychanski R, Moore L, et al.
338 Perioperative intravenous lidocaine infusion for postoperative pain control: a meta-analysis of
339 randomized controlled trials. *Can J Anaesth* 2011; 58: 22–37.
- 340 19. Jeong HJ, Lin D, Li L, Zuo Z. Delayed treatment with lidocaine reduces mouse microglial
341 cell injury and cytokine production after stimulation with lipopolysaccharide and interferon γ .
342 *Anesth Analg* 2012; 114:856–861.
- 343 20. Suto T, Obata H, Tobe M, Oku H, Yokoo H, Nakazato Y. Longterm effect of epidural
344 injection with sustained-release lidocaine particles in a rat model of postoperative pain. *Br J*
345 *Anaesth* 2012;109:95 7–967.
- 346 21. Obreja O, Hirth M, Turnquist B, Rukwied R, Ringkamp M, Schmelz M. The differential
347 effects of two sodium channel modulators on the conductive properties of C-fibers in pig
348 skin in vivo. *Anesth Analg* 2012; 115:56 0–571.
- 349 22. Hamp T, Krammel M, Weber U, Schmid R, Graf A, Plöchl W. The effect of a bolus dose
350 of intravenous lidocaine on the minimum alveolar concentration of sevoflurane: a
351 prospective, randomized, double-blinded, placebo-controlled trial. *Anesth Analg* 2013;
352 117:32 3–328.
- 353 23. Cho AR, Kwon JY, Kim KH, Lee HJ, Kim HK, Kim ES, et al. The effects of anesthetics
354 on chronic pain after breast cancer surgery. *Anesth Analg* 2013; 116:68 5–693.

355 24. Petrenko AB, Ishii H, Kohno T, Baba H. When similar is not alike: decreased sensory
356 thresholds after intravenous infusion of remifentanil may not be remifentanil-induced
357 hyperalgesia. *Anesth Analg* 2012; 115:977.